What is the 13F Pro Quality Score for AGEN?

13F Pro ranks AGENUS INC (AGEN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AGEN's current score at https://13fpro.ai/research/AGEN (free sign-up required for the full ranking).

Where does 13F Pro source AGEN data?

All AGENUS INC fundamentals and ownership data come directly from SEC EDGAR. AGENUS INC files with the SEC under CIK 1098972. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AGEN in?

AGENUS INC (AGEN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AGEN research updated on 13F Pro?

AGEN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AGENUS INC(AGEN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1098972 AGEN stock profile & AI dashboard →

13F Pro Quality Score

51.2/100

Rank #1,409 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

55.4/100

Profitability

94.5/100

Balance Sheet

96.9/100

Earnings Quality

30.0/100

Free Cash Flow

7.4/100

Institutional Flow

9.5/100

Revenue Scale

18.8/100

Dilution Risk

14.9/100

AGEN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AGENUS INC (AGEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AGEN at 51.2/100 on a 32-signal composite quality model, placing it at rank #1,409 of 2,879 stocks — the top half of the AI-ranked universe. AGEN scores in the top quartile across balance sheet strength (96.9), profitability (94.5). Areas of concern include free cash flow (7.4) and institutional flow (9.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AGENUS INC reports quarterly revenue of $33.7M, net income of $39.2M, free cash flow of $-36.0M. Top institutional holders of AGEN by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, Siren, L.L.C., based on the most recent SEC filings. AGEN trades on the Nasdaq exchange and files with the SEC under CIK 1098972. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AGENUS INC directly from SEC EDGAR. AGENUS INC's 13F Pro composite quality score has ranged between 10 and 52 since 2021, currently 51.2 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about AGENUS INC

Quirks, history, and lore behind AGEN — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on immuno-oncology.
2
The Numbers
A small-cap biotech with limited product revenue, surviving largely on partnership milestones and royalties — the classic pre-profitability biotech math.
3
The History
Founded in the 1990s, the company built an early foundation in antibody technology and has spent decades translating that platform into potential cancer therapies.
4
The Secret
Its secret weapon is a proprietary CTLA-4 antibody and a broader pipeline of checkpoint modulators designed to turbocharge the immune system against tumors.
5
The Lore
The company has inked deals with major pharma players including Gilead and Incyte, collecting partnership dollars while its own pipeline matures — the biotech waiting game at its finest.
6
The Giveaway
Its ticker is practically a shout — AGEN — and its full name rhymes with "ageless," fitting for a company betting its future on cancer immunotherapy built on decades of antibody science.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$33.7M

Net Income

Q1 2026

$39.2M

Free Cash Flow

Q1 2026

$-36.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.4% YoY

$114.2MFY 2025

FY21 $295.7MFY22 $98.0MFY24 $103.5MFY25 $114.2M

Net Income

+98.7% YoY

$-3.1MFY 2025

FY21 —FY22 —FY24 $-232.3MFY25 $-3.1M

Operating Income

+83.3% YoY

$-20.2MFY 2025

FY21 $25.7MFY22 $-179.4MFY24 $-120.5MFY25 $-20.2M

EPS (Diluted)

+100.0% YoY

$0.00FY 2025

FY21 $-0.11FY22 $-15.64FY24 $-10.59FY25 $0.00

Total Assets

+0.2% YoY

$226.8MFY 2025

FY21 $466.0MFY22 $413.6MFY24 $226.3MFY25 $226.8M

Total Debt

+149.0% YoY

$89.3MFY 2025

FY21 $13.6MFY22 $13.2MFY24 $35.9MFY25 $89.3M

Op. Cash Flow

+51.2% YoY

$-77.2MFY 2025

FY21 $10.1MFY22 $-175.4MFY24 $-158.3MFY25 $-77.2M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$114.2M +10.4%	$103.5M +5.5%	$98.0M -66.8%	$295.7M +235.3%	$88.2M +139.7%	$36.8M
Net Income	$-3.1M +98.7%	$-232.3M	—	—	—	—
Operating Income	$-20.2M +83.3%	$-120.5M +32.9%	$-179.4M -796.9%	$25.7M +122.0%	$-117.2M +5.3%	$-123.8M
EPS (Diluted)	$0.00 +100.0%	$-10.59 +32.3%	$-15.64 -14118.2%	$-0.11 +89.5%	$-1.05	—
Total Assets	$226.8M +0.2%	$226.3M -45.3%	$413.6M -11.2%	$466.0M +117.2%	$214.5M +57.3%	$136.4M
Total Debt	$89.3M +149.0%	$35.9M +172.6%	$13.2M -2.9%	$13.6M -31.3%	$19.7M +47.6%	$13.4M
Operating Cash Flow	$-77.2M +51.2%	$-158.3M +9.7%	$-175.4M -1828.7%	$10.1M +107.3%	$-139.1M -6.1%	$-131.1M

Get alerted when AGEN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AGENUS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AGEN

VANGUARD CAPITAL MANAGEMENT LLC
$4.8M1,440,232 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$4.0M1,195,109 sh
Siren, L.L.C.
$3.6M1,064,250 sh
MARSHALL WACE, LLP
$2.3M688,203 sh
BlackRock, Inc.
$1.8M545,662 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.2M348,395 sh
MORGAN STANLEY
$988.0K295,821 sh
RENAISSANCE TECHNOLOGIES LLC
$954.1K285,646 sh
Man Group plc
$931.8K278,980 sh
RAYMOND JAMES FINANCIAL INC
$800.1K239,554 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$4.8M	1,440,232
VANGUARD PORTFOLIO MANAGEMENT LLC	$4.0M	1,195,109
Siren, L.L.C.	$3.6M	1,064,250
MARSHALL WACE, LLP	$2.3M	688,203
BlackRock, Inc.	$1.8M	545,662
GEODE CAPITAL MANAGEMENT, LLC	$1.2M	348,395
MORGAN STANLEY	$988.0K	295,821
RENAISSANCE TECHNOLOGIES LLC	$954.1K	285,646
Man Group plc	$931.8K	278,980
RAYMOND JAMES FINANCIAL INC	$800.1K	239,554

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AGEN on your watchlist

Track score changes the day AGENUS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AGEN a good stock to buy?

13F Pro's AI-powered analysis of AGENUS INC (AGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AGEN are available on the AGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AGEN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AGENUS INC's investment landscape.